
usd aug pm et
summari global supplier over-the-counter over-the-count non-prescript health care product
gener pharmaceut
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug pm stock trade
drop full-year declin led
consum revenu
continu see price pressur exist
product unfavor foreign currenc
impact intern revenu one
bright spot sale gener
segment revenu return
posit territori sale growth yoy
follow sever year declin
improv gener driven new
product launch enough off-set
lower price older gener
oper margin consum drop
yoy face rise
commod cost price pressur over-the-counter
retail pharmaci chain reduc
price power explain much yoy
drop total oper incom
current challeng larg back-tax
assess sought irish
govern amount approxim
euro ir
amount case could requir
year resolv present signific
liquid risk view
due tax liabil risk challeng
environ face attempt divest
gener segment stabil struggl
over-the-counter product busi firm like
limit earn growth deal price
pressur store-brand over-the-counter product
driven consolid custom whose
also expect declin volum
domest consum busi due focu
store-label over-the-counter product come
product consum put bodi
think brand name psycholog
import economi
experienc low unemploy strong
wage gain think shopper like
opt higher-pr brand over-the-counter product
store label suppli
target ep
estim -- histor forward
price-to-earnings averag due poor growth outlook
elev risk aris materi tax
disput downsid risk view includ
rule failur rx-to-otc
produc mani commodity-lik product
limit abil control price also see focu
suppli store-label over-the-counter product drag
long-term growth often perceiv
lower qualiti brand view think
consum percept qualiti import
health care product especi economi
well shopper better-posit opt
signific liquid risk relat on-going tax
disput irish govern could
result nearli tax liabil
nov ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead global health care supplier develop manufactur
distribut over-the-count over-the-counter prescript pharmaceut nutrit product activ
pharmaceut ingredi api consum product world largest manufactur
over-the-counter pharmaceut product privat label store brand market store brand product contain
activ ingredi advertis brand lower cost consum store brand
retail sell product store anoth chosen brand name
consum health product consum product busi gener total
revenu compris broad line over-the-counter store brand product compar qualiti
efficaci advertis brand product compani typic gener revenu contract
provid store-label product retail pharmaci supermarket mass merchandis
gener sam club amazon aldi petsmart petco cost retail store brand
product typic much lower compar nation advertis brand-nam product
retail therefor price store brand product compet nation brand product yet realiz
greater gross profit store-brand item
major consum product categori includ analges cough/cold/allergy/sinu medic
gastrointestin smoke cessat item exampl store brand analges acetaminophen
activ ingredi brand tylenol consum product also includ broad rang household
gener gener sement gener roughli total revenu focus
develop manufactur sale gener prescript pharmaceut primarili market
manufactur oper base israel gener product includ oral product cream
ointment lotion gel shampoo foam suppositori spray liquid suspens solut
well nasal spray oral liquid transderm product compani also manufactur market
brand prescript drug licens firm
gener segment primarili sell product sourc joint ventur jv establish last
sever year three major drug wholesal nation pharmaci chain three primari
sourc jv red oak combin wbad combin walgreen
claruson combin
increas purchas power garner major purchas jv one driver
signific price deflat mani gener drug sell calcul gener
segment sale declin precipit
major develop march sold tysabri royalti right royalti pharma
billion plu potenti payment royalti earn meet specifi
threshold think price low end note declin tysabri sale competit
multipl sclerosi market tysabri gener million million royalti
decemb report irish offic revenu commiss gave notic
compani owe tax total billion euro approxim billion relat transact
execut subsidiari pharma amount compar cash equival million
decemb result risk larg unfund liabil tax assess stand
claim incom relat transact appropri report trade incom tax
howev disput commiss claim transact treat gain
tax appeal assess payment due process complet
could take year
financi trend total revenu declin period
adjust pre-tax incom margin declin around due declin revenu
contract profit margin adjust ep declin earn
interest tax amort ebita cover interest expens
reason leverag level view
global oper
senior director
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc august technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
e-estim na-not avail nm-not meaning nr-not rank ur-und review prior fiscal year end jun
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth
driven slowdown novel drug approv
activ potenti new price regul
neg partial off-set
upcom favor period patent
expir also
expect gener maker continu struggl
grow earn lower cost foreign
competit continu prosper
banner year new brand
drug fda see slowdown
total novel drug approv
fda signific
surg versu combin approv
growth sub-industri
versu averag
new drug launch appear slow
howev fda approv
novel drug year june
period also observ
yoy declin spend
pharmaceut think
portend effort maintain margin sluggish
revenu growth year ahead
pharmaceut also face increas
risk potenti new drug price regul
juli presid indic
administr work new rule set
govern drug price use intern
index accord wall street journal
studi govern health system develop
countri like england norway canada often
pay less major brand
 center medicar medicaid
servic think intern
index rule would like drive higher price
foreign market lower one
would like still neg
overal impact sub-industri revenu
administr effort date lower drug
price regul
success intern index
signific risk weigh outlook
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
posit brand drug sale
beyond brand firm make lion
share sub-industri market cap outlook
gener maker neg previous
anda would declin sever deflat
drove competitor industri
seem play
six-month move averag anda june
recent peak
longer think fewer competitor
enough stabil gener industri
howev india-bas gener maker
like take market share develop nation
firm due lower product cost --
india-bas produc oper
estim averag gross margin
versu top western
drop broader composit
year-to-d juli
pharmaceut
gain
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
lower target ep estim
long-term averag forward price-to-earnings expect below-averag
ep growth result challeng gener unit drop ep
estim faster-than-expect
deterior gener busi sale yoy gross profit
margin fell approxim bp worst perform quarter
gener segment revenu saw sale declin yoy
sustain downward trend sinc increas competit custom
consolid drive declin announc august
plan exit busi although still remain unclear form exit
take adjust pre-tax incom first nine month
yoy much reason believ better point given
weak sale outlook margin pressur compani face /colin scarola
keep target price below-p
forward ep estim reflect view
compani like continu face challeng particularli relat
recent tysabri sale howev posit news
spin-off prescript pharmaceut busi sale
focu consum busi also see increas stabil recent
manag chang keep ep estim
respect trade near estim fair valu expect
share outperform broader market next month /jim
analyst research note compani news
et cfra keep hold opinion share perrigo compani plc
cut target price ep estim
histor forward price-to-earnings averag due poor growth outlook keep
ep estim drop ep
vs beat consensu difficult quarter
sale fell yoy oper profit least yoy
segment consum sale total yoy yoy drop
oper incom consum busi maintain strong market
share store-brand over-the-counter health product think macro shift toward on-line
shop hurt perform segment prescript drug segment
saw sale growth yoy oper profit fell yoy price
pressur gener drug continu due intens competit
consolid custom view poor long-term growth outlook
think reflect low valuat therefor
neutral share /colin scarola
et cfra keep hold opinion share perrigo compani plc
lift target price ep
estim -- long-term forward price-to-earnings averag due poor growth
outlook elev risk aris larg tax assess
disput drop ep estim
ep vs beat consensu sale
yoy driven yoy declin consum america
revenu consum intern segment respect
prescript segment grew sale yoy return sale growth
new product launch larg declin adjust pre-tax
incom fell yoy faster sale firm saw signific margin
contract across segment think relat consolid
pharmaci give custom greater purchas power poor
growth outlook neutral share despit low valuat rel
et cfra keep hold opinion share perrigo compani plc
lift target price ep
estim -- long-term forward price-to-earnings averag due elev risk
aris recent notic larg tax assess loss price power
lift ep estim start ep
vs miss consensu sale yoy
driven yoy sale declin over-the-counter health care busi
sale yoy drop sale gener prescript drug busi
product price pressur consolid
pharmaci led greater price power downstream custom
view e-commerc hurt store-brand over-the-counter sale see sign
trend slow either leav us poor long-term outlook
growth also signific tax liabil risk view relat
past tax assess irish govern challeng
pm et cfra keep hold opinion share perrigo compani plc
lower target price ep
estim long-term averag forward price-to-earnings due elev
risk see aris recent notic larg tax assess maintain
ep estim share around today
compani report irish offic revenu commiss
gave notic owe tax total euro relat
transact execut subsidiari pharma current cash equival
total believ incom relat transact
appropri report trade incom tax disput
commiss claim transact treat gain tax
appeal assess payment due
process complet could take year remain neutral
share due uncertainti around whether pay larg tax
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
